Baumann, Sira M.
De Stefano, Pia
Kliem, Paulina S. C.
Grzonka, Pascale
Gebhard, Caroline E.
Sarbu, Oana E.
De Marchis, Gian Marco
Hunziker, Sabina
Rüegg, Stephan
Kleinschmidt, Andreas
Pugin, Jérôme
Quintard, Hervé
Marsch, Stephan
Seeck, Margitta
Sutter, Raoul
Funding for this research was provided by:
Universitätsspital Basel
University of Basel
Article History
Received: 26 June 2023
Accepted: 28 July 2023
First Online: 5 August 2023
Declarations
:
: In accordance with the 1964 Declaration of Helsinki and its subsequent revisions, the local ethics committee (Ethikkommission Nordwest- und Zentralschweiz) granted approval for the study. The requirement for obtaining patient consent was waived.
: Not applicable.
: SMB declares no competing interests. PDS was supported by the Swiss National Science Foundation (163398, CRS115-180365) and is supported by the 2022 Swiss League Against Epilepsy Research Support Prize. PSCK declares no competing interests. PG declares no competing interests. CEG has received speakers’ fees from Sanofi Genzyme, travel support from Siemens Healthineers, and research support from the Novartis Foundation, Switzerland, and Bayer Pharmaceuticals. OEG declares no competing interests. GMDM has been receiving support from the Swiss National Science Foundation (Nr 32003B_200573, Nr. PBBEP3_139388); Spezialprogramm Nachwuchsförderung Klinische Forschung, University of Basel; Science Funds (Wissenschaftspool) of the University Hospital Basel; Swiss Heart Foundation; ProPatient Foundation Basel; Bangerter-Rhyner-Stiftung; Swisslife Jubiläumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr Ettore Balli; De Quervain research grant; Thermo Fisher GmbH; Novartis grant; travel honoraria by Bayer and BMS/Pfizer; speaker honoraria by Bayer and Medtronic; consultant honoraria by Bayer and Novartis. He is member of the Steering Committee of PACIFIC Stroke (NCT04304508). Industry payments are made to the research fund of the University Hospital Basel. SH is supported by the Swiss National Foundation (SNF) (Ref 10001C_192850/1 and 10531C_182422), the Gottfried Julia Bangerter-Rhyner Foundation (8472/HEG-DSV), and the Swiss Society of General Internal Medicine (SSGIM). SR received unconditional research grants from UCB-pharma. He received honoraria from serving on the scientific advisory boards of Angellini/Arvelle, Bial, Eisai, GW, and UCB-pharma, and from serving as a consultant for Angellini/Arvelle, Eisai, Pfizer, Novartis, Sandoz, and UCB-pharma. He does not hold any stocks of any pharmaceutical industries or manufacturers of medical devices. He received funding from UCB-pharma, and Swiss National Science Foundation Grants: Grant Number 320030_169379/1 and coapplicant for grants numbers 33CM30_125115/1 and 33CM30_140338/1; he disclosed that he is the past-president of the Swiss League against Epilepsy (no payments). AK has received honoraria for consulting from Abbvie, EliLilly, Lundbeck, Mitsubishi Tanabe, Novartis, and TEVA that were paid to a teaching and research fund at the University Hospital Geneva. JP declares no competing interests. HQ declares no competing interests. SM declares no competing interests. MS is a shareholder of Epilog NV (Ghent, Belgium). She received speaker's fees from Philips and Desitin. She received grants from the Swiss National Science Foundation (163398, CRS115-180365). RS received research grants from the Swiss National Foundation (Ref 320030_169379), the Research Fund of the University Basel, the Scientific Society Basel, and the Gottfried Julia Bangerter-Rhyner Foundation. He received personal grants from UCB-pharma and holds stocks from Novartis, Roche, Alcon, and Johnson & Johnson.